Cargando…

Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies

The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ail, Divya, Nava, Diane, Hwang, In Pyo, Brazhnikova, Elena, Nouvel-Jaillard, Céline, Dentel, Alexandre, Joffrois, Corentin, Rousseau, Lionel, Dégardin, Julie, Bertin, Stephane, Sahel, José-Alain, Goureau, Olivier, Picaud, Serge, Dalkara, Deniz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396314/
https://www.ncbi.nlm.nih.gov/pubmed/37531424
http://dx.doi.org/10.1126/sciadv.adg8163
_version_ 1785083733440724992
author Ail, Divya
Nava, Diane
Hwang, In Pyo
Brazhnikova, Elena
Nouvel-Jaillard, Céline
Dentel, Alexandre
Joffrois, Corentin
Rousseau, Lionel
Dégardin, Julie
Bertin, Stephane
Sahel, José-Alain
Goureau, Olivier
Picaud, Serge
Dalkara, Deniz
author_facet Ail, Divya
Nava, Diane
Hwang, In Pyo
Brazhnikova, Elena
Nouvel-Jaillard, Céline
Dentel, Alexandre
Joffrois, Corentin
Rousseau, Lionel
Dégardin, Julie
Bertin, Stephane
Sahel, José-Alain
Goureau, Olivier
Picaud, Serge
Dalkara, Deniz
author_sort Ail, Divya
collection PubMed
description The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation.
format Online
Article
Text
id pubmed-10396314
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-103963142023-08-03 Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies Ail, Divya Nava, Diane Hwang, In Pyo Brazhnikova, Elena Nouvel-Jaillard, Céline Dentel, Alexandre Joffrois, Corentin Rousseau, Lionel Dégardin, Julie Bertin, Stephane Sahel, José-Alain Goureau, Olivier Picaud, Serge Dalkara, Deniz Sci Adv Biomedicine and Life Sciences The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation. American Association for the Advancement of Science 2023-08-02 /pmc/articles/PMC10396314/ /pubmed/37531424 http://dx.doi.org/10.1126/sciadv.adg8163 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Ail, Divya
Nava, Diane
Hwang, In Pyo
Brazhnikova, Elena
Nouvel-Jaillard, Céline
Dentel, Alexandre
Joffrois, Corentin
Rousseau, Lionel
Dégardin, Julie
Bertin, Stephane
Sahel, José-Alain
Goureau, Olivier
Picaud, Serge
Dalkara, Deniz
Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title_full Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title_fullStr Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title_full_unstemmed Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title_short Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
title_sort inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396314/
https://www.ncbi.nlm.nih.gov/pubmed/37531424
http://dx.doi.org/10.1126/sciadv.adg8163
work_keys_str_mv AT aildivya induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT navadiane induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT hwanginpyo induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT brazhnikovaelena induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT nouveljaillardceline induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT dentelalexandre induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT joffroiscorentin induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT rousseaulionel induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT degardinjulie induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT bertinstephane induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT saheljosealain induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT goureauolivier induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT picaudserge induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies
AT dalkaradeniz induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies